Financial Review: Accelerate Diagnostics (AXDX) vs. Boston Scientific Corporation (BSX)
Accelerate Diagnostics (NASDAQ: AXDX) and Boston Scientific Corporation (NYSE:BSX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
44.4% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 90.5% of Boston Scientific Corporation shares are held by institutional investors. 51.4% of Accelerate Diagnostics shares are held by insiders. Comparatively, 0.7% of Boston Scientific Corporation shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Accelerate Diagnostics and Boston Scientific Corporation’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Accelerate Diagnostics||$1.29 million||996.65||-$61.92 million||($1.23)||-18.90|
|Boston Scientific Corporation||$8.71 billion||4.58||$2.31 billion||$0.58||50.14|
Boston Scientific Corporation has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Boston Scientific Corporation, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Accelerate Diagnostics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Boston Scientific Corporation has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Accelerate Diagnostics and Boston Scientific Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Boston Scientific Corporation||0||4||12||0||2.75|
Accelerate Diagnostics presently has a consensus target price of $33.00, suggesting a potential upside of 41.94%. Boston Scientific Corporation has a consensus target price of $30.19, suggesting a potential upside of 3.82%. Given Accelerate Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Accelerate Diagnostics is more favorable than Boston Scientific Corporation.
This table compares Accelerate Diagnostics and Boston Scientific Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Boston Scientific Corporation||9.04%||23.62%||9.01%|
Boston Scientific Corporation beats Accelerate Diagnostics on 8 of the 13 factors compared between the two stocks.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Receive News & Stock Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related stocks with our FREE daily email newsletter.